Page last updated: 2024-12-11

noroxycodone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

noroxycodone: RN given for (5alpha)-isomer; metabolite of oxycodone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5489120
CHEMBL ID3527426
CHEBI ID168092
SCHEMBL ID4705032
MeSH IDM0207533

Synonyms (23)

Synonym
(4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-1,2,3,4,5,6,7a,13-octahydro-4,12-methanobenzouro[3,2-e]isoquinolin-7-one
CHEBI:168092
morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-, (5alpha)-
morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-, (5alpha)- (9ci)
57664-96-7
(5alpha)-4,5-epoxy-14-hydroxy-3-methoxymorphinan-6-one
noroxycodone
95q949779d ,
einecs 260-887-7
unii-95q949779d
norcodeinone, dihydro-14-hydroxy-
morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-, (5.alpha.)-
oxycodone hydrochloride impurity c [ep impurity]
SCHEMBL4705032
RIKMCJUNPCRFMW-ISWURRPUSA-N
(4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-2,3,4,4a,5,6-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7ah)-one
CHEMBL3527426 ,
(1s,5r,13r,17s)-17-hydroxy-10-methoxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
bdbm50505669
oxykodon
DTXSID60973261
Q27271817
(4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-1,2,3,4,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively."( The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
Kalso, E; Olkkola, KT; Pöyhiä, R; Seppälä, T, 1992
)
0.28
" AUC values were also calculated for the pharmacodynamic variable "drug effect," scored on a 100 mm visual analog scale."( Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Benziger, DP; Burke, BE; Fitzmartin, RD; Goldenheim, PD; Kaiko, RF; Reder, RF, 1996
)
0.29
" Mean elimination half-life was prolonged in uremic patients due to increased volume of distribution and reduced clearance."( The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
Kirvela, M; Lindgren, L; Olkkola, KT; Seppala, T, 1996
)
0.29
" Oral administration of oxycodone to the SD rat is a poor model of the human for the study of the pharmacodynamic effects of oxycodone."( Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
Chan, S; Edwards, SR; Smith, MT; Wyse, BD, 2008
)
0.35
" Plasma concentrations of oxycodone and its oxidative metabolites were measured for 48 h, and pharmacodynamic effects were evaluated."( Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2010
)
0.36
" Most of the pharmacokinetic changes in oral oxycodone were seen in the elimination phase, with modest effects by itraconazole on its peak concentration, which was increased by 45% (P=0."( Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2010
)
0.36
" We performed a three-way, placebo-controlled, double-blind cross-over study to assess the pharmacokinetic and pharmacodynamic consequences of drug interactions with oxycodone."( Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Drewe, J; Hammann, F; Krähenbühl, S; Kummer, O; Moser, C; Schaller, O, 2011
)
0.37
"Inhibition of CYP3A4 by ketoconazole increases the exposure and some pharmacodynamic effects of oxycodone."( Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Drewe, J; Hammann, F; Krähenbühl, S; Kummer, O; Moser, C; Schaller, O, 2011
)
0.37
" There were no significant sex-related differences in any of the pharmacokinetic parameters."( Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Aantaa, R; Kuusniemi, K; Liukas, A; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Virolainen, P, 2011
)
0.37
"The aim of this study is to evaluate the pharmacokinetic profile of oxycodone and three of its metabolites, noroxycodone, oxymorphone and noroxymorphone after intravenous administration in Chinese patients with pain."( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014
)
0.62
"Pharmacokinetic parameters showed that mean values of C(max), AUC(0-t) and AUC(0-∞) of oxycodone were dose dependent, whereas Tmax and t(1/2) were not."( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014
)
0.4
" Preterm neonates were found to have the highest pharmacokinetic variability out of the study population."( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017
)
0.46
"Oxycodone elimination is slower and pharmacokinetic variability more pronounced in neonates when compared to older infants."( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017
)
0.46
" The pharmacokinetics including the relatively short half-life of oxycodone in patients with ESRD with or without haemodialysis and the absence of unconjugated active metabolites indicate that oxycodone can be used at usual doses in patients requiring dialysis."( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" The variation in plasma morphine concentrations was higher than that of oxycodone, consistent with the lower bioavailability of morphine."( Morphine or oxycodone in cancer pain?
Heiskanen, TE; Kalso, EA; Ruismäki, PM; Seppälä, TA, 2000
)
0.31

Dosage Studied

Haemodialysis performed 6-10 h after dosing removed 10% of the administered dose. There was a poor correlation between concentrations of both oxycodone and noroxycodone in plasma and saliva.

ExcerptRelevanceReference
"1 after titration with IR oxycodone dosed qid."( Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.
Davis, M; Reder, RF; Stambaugh, H; Stambaugh, JE; Stambaugh, MD, 2001
)
0.31
" There was a poor correlation between concentrations of both oxycodone and noroxycodone in plasma and saliva over a range of times following dosing (r (2) = 0."( Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?
Anderson, H; Charles, B; Hardy, J; Norris, R; O'Shea, A, 2012
)
0.61
" Plasma concentration of oxycodone and its metabolites were measured up to 8 hours after administration as follows: on day 1, CR oxycodone was administered alone; on day 2, CR oxycodone was administered with aprepitant (125 mg, at the same time of oxycodone dosing in the morning)."( Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Chayahara, N; Fujiwara, Y; Imamura, Y; Kiyota, N; Minami, H; Mukohara, T; Shimada, T; Toyoda, M, 2014
)
0.4
"Haemodialysis performed 6-10 h after dosing removed ∼10% of the administered dose of oxycodone predominantly as unconjugated oxycodone and noroxycodone or conjugated oxymorphone and noroxymorphone."( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenanthrenesAny benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Oxycodone Pathway, Pharmacokinetics46

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)199.82000.21005.553710.0000AID1526751
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)Km20.10000.47704.03089.0000AID1526737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1526736Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1526733Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.5 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1526731Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.05 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1526752Passive membrane permeability by LC-MS/MS analysis based PAMPA2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1526751Inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1211695Transactivation of human PXR transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM by luciferase reporter gene assay2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1211699Transactivation of mouse CAR1 transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM after 24 hrs by luciferase reporter gene assay2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1211696Transactivation of rat PXR at 0.1 to 30 uM after 24 to 48 hrs by cell-based luciferase reporter gene assay2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1211701Transactivation of human CAR1 Ala retention mutant transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM after 24 hrs by luciferase reporter gene assay2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1526734Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.05 to 0.5 uM incubated for 2 mins in presence of 2 mM MPP+ by LC-MS/MS analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1526737Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1211697Transactivation of human AhR at 0.1 to 30 uM after 24 to 48 hrs by cell-based luciferase reporter gene assay2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1526750Substrate activity at human OCT3 expressed in HEK293 cells assessed as increase in compound uptake up to 200 uM incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1211698Transactivation of human CAR1 transfected in human HepG2 cells assessed as CYP2B6 expression at 1 to 30 uM after 24 hrs by luciferase reporter gene assay2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.
AID1526732Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.1 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (8.33)18.2507
2000's17 (35.42)29.6817
2010's23 (47.92)24.3611
2020's4 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.63 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (27.45%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (5.88%)4.05%
Observational0 (0.00%)0.25%
Other34 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]